In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study.
暂无分享,去创建一个
J. Kulisevsky | P. Martínez-Martín | P. Pástor | M. Grothe | B. Pascual-Sedano | A. Adarmes-Gómez | F. Carrillo | S. Jesús | M. Labrador-Espinosa | P. Mir | J. F. Martin-Rodriguez | D. Santos-García | Javier Rúiz Martínez | Jorge Hernández Vara | O. de Fábregues‐Boixar | T. de Deus Fonticoba | Isabel González Aramburu | Berta Solano Vila | F. C. Padilla | D. Santos‐García | F. R. Lora | M. A. Barberá | So Arroyo | Anna Cots Foraster | Mercedes Pueyo Morlans | Jon Infante Ceberio | D. Macías-García | Elena Iglesias Camacho | P. Franco-Rosado | J. I. Ceberio | B. S. Vila | A. C. Foraster | M. P. Morlans | I. G. Aramburu | J. H. Vara
[1] N. Bohnen,et al. Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease , 2020, Movement disorders : official journal of the Movement Disorder Society.
[2] S. Teipel,et al. Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease , 2020, Neurology.
[3] J. Kulisevsky,et al. Longitudinal intracortical diffusivity changes in de-novo Parkinson's disease: A promising imaging biomarker. , 2019, Parkinsonism & related disorders.
[4] T. Druzgal,et al. Lower volume, more impairment: reduced cholinergic basal forebrain grey matter density is associated with impaired cognition in Parkinson disease , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.
[5] Stefan Teipel,et al. The corticotopic organization of the human basal forebrain as revealed by regionally selective functional connectivity profiles , 2018, Human brain mapping.
[6] S. Lehéricy,et al. Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.
[7] A. Strafella,et al. Brain degeneration in Parkinson’s disease patients with cognitive decline: a coordinate-based meta-analysis , 2018, Brain Imaging and Behavior.
[8] M. Politis,et al. Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson’s disease , 2018, Brain : a journal of neurology.
[9] Nicola J. Ray,et al. Recent Advances in Cholinergic Imaging and Cognitive Decline—Revisiting the Cholinergic Hypothesis of Dementia , 2018, Current Geriatrics Reports.
[10] Nicola J. Ray,et al. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson’s disease , 2017, Brain : a journal of neurology.
[11] L. Grinberg,et al. In Vivo Volumetry of the Cholinergic Basal Forebrain , 2018 .
[12] C. Normann,et al. Contribution of the Cholinergic System to Verbal Memory Performance in Mild Cognitive Impairment , 2016, Journal of Alzheimer's disease : JAD.
[13] J. Kulisevsky,et al. COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global –clinical evaluations, serum biomarkers, genetic studies and neuroimaging– prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression , 2016, BMC Neurology.
[14] N. Schuff,et al. Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection , 2015, The Lancet Neurology.
[15] S. Gentleman,et al. Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer’s and Parkinson’s disease , 2015, Acta Neuropathologica.
[16] Richard A Armstrong,et al. When to use the Bonferroni correction , 2014, Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians.
[17] Stefan J. Teipel,et al. Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer’s disease dementia , 2014, Journal of Neurology.
[18] Y. Sohn,et al. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[19] Y. Sohn,et al. Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status , 2012, Neurobiology of Aging.
[20] F. Piras,et al. Hippocampal abnormalities and memory deficits in Parkinson disease , 2012, Neurology.
[21] H. Heinsen,et al. Atrophy of the Cholinergic Basal Forebrain Over the Adult Age Range and in Early Stages of Alzheimer's Disease , 2012, Biological Psychiatry.
[22] Stefan Klöppel,et al. Multicenter stability of diffusion tensor imaging measures: A European clinical and physical phantom study , 2011, Psychiatry Research: Neuroimaging.
[23] T. Anderson,et al. Grey matter atrophy in cognitively impaired Parkinson's disease , 2011, Journal of Neurology, Neurosurgery & Psychiatry.
[24] R. Albin,et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease , 2010, Brain : a journal of neurology.
[25] Jaime Kulisevsky,et al. Parkinson's disease‐cognitive rating scale: A new cognitive scale specific for Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[26] H. Hanyu,et al. MR features of the substantia innominata and therapeutic implications in dementias , 2007, Neurobiology of Aging.
[27] H. Hanyu,et al. Differences in MR features of the substantia innominata between dementia with Lewy bodies and Alzheimer’s disease , 2005, Journal of Neurology.
[28] I. McKeith,et al. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. , 2004, Brain : a journal of neurology.